Category

Daily Briefs

Jan 12
0

Daily Brief Financials: Mitsubishi UFJ Financial (MUFG), Yibin City Commercial Bank Co Ltd, Upstart Holdings and more

By | Daily Briefs, Financials

In today’s briefing:

  • Opportunity Within Europe and Japan; EURO STOXX 50 and TOPIX/Nikkei 225 Near Major Breakouts
  • Yibin Bank (2596 HK): 100% IPO Float Fails to Secure Global Index Inclusion
  • Upstart Holdings Inc. Breaks Barriers with High-Tech Automation for Explosive Efficiency Gains! – Major Drivers

Opportunity Within Europe and Japan; EURO STOXX 50 and TOPIX/Nikkei 225 Near Major Breakouts

By Joe Jasper

  • Our bullish outlook on global equities (MSCI ACWI) remains intact. Actionable Themes today include Financials, Energy, and Consumer Discretionary (European Luxury Retailers)
  • We view this pullback as a buying opportunity and we are watching for $116-$117 support to hold on ACWI-US; this is an important resistance-turned-support level dating back to July 2024.
  • Europe and Japan are on the cusp of major breakouts above critical resistance levels of 5000-5120 on the EURO STOXX 50 and 2740-2820 on the TOPIX

Yibin Bank (2596 HK): 100% IPO Float Fails to Secure Global Index Inclusion

By Dimitris Ioannidis

  • Yibin City Commercial Bank Co Ltd (2596 HK) is scheduled to debut on the HKEX on 13 January 2025 at a market capitalization of ~$1.6bn.
  • The IPO free float is 100% as the offered shares represent all the listed shares. However, the significant amount of unlisted shares result in a low fcap.
  • The security can be added at the June 2025 review if the stock price mimics the IPO debut of Bloks (325 HK) and surges by ~84%.

Upstart Holdings Inc. Breaks Barriers with High-Tech Automation for Explosive Efficiency Gains! – Major Drivers

By Baptista Research

  • Upstart Holdings, Inc., a company at the forefront of fintech innovation using artificial intelligence, has reported its third quarter financial results for 2024.
  • The company showcased significant developments while balancing both growth potentials and present challenges.
  • Positively, Upstart demonstrated substantial growth momentum, with a reported 43% sequential growth in lending volume and a return to positive adjusted EBITDA, reaching this milestone a quarter ahead of schedule.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars
Sign Up for Free


Jan 12
0

Daily Brief Health Care: Qingdao Haier Biomedical Lt, Halozyme Therapeutics and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • China Healthcare Weekly (Jan.12) – Haier Biomedical and RAAS Terminated Their Merger
  • Halozyme Therapeutics Inc.: Intellectual Property Portfolio & Expansion Fueling Our ‘Outperform’ Rating! – Major Drivers

China Healthcare Weekly (Jan.12) – Haier Biomedical and RAAS Terminated Their Merger

By Xinyao (Criss) Wang

  • Since the room for China’s medical insurance fund to continue to increase reimbursement for high quality innovative drugs is still large, we are optimistic about 2025 NRDL negotiation.
  • Although it’s inevitable trend for commercial insurance to cover innovative drugs, it won’t truly improve the payment end until the contribution of commercial insurance to hospital revenue increase to 10-15%.
  • Due to the complexity of the transaction, Haier Biomedical and RAAS terminated their merger. We think disagreements would easily emerge regarding the core issue in this transaction (i.e. the price).

Halozyme Therapeutics Inc.: Intellectual Property Portfolio & Expansion Fueling Our ‘Outperform’ Rating! – Major Drivers

By Baptista Research

  • Halozyme Therapeutics reported strong financial and operational results for the third quarter of 2024.
  • The company achieved a 34% increase in total revenues, reaching $290 million, primarily driven by a 36% increase in royalty revenues, which set a new record at $155 million.
  • The growth stemmed largely from the expanded adoption of the ENHANZE drug delivery technology, especially through products like DARZALEX subcutaneous, Phesgo, and VYVGART Hytrulo.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars
Sign Up for Free


Jan 12
0

Top 10 Highlights from the APAC PE, VC and Startup Ecosystem this Week – 12 Jan 2025

By | Private Markets, Smartkarma Newswire

Top ten highlights from the APAC PE, VC, and startup ecosystem this week:

  1. Indian Startups See Decrease in Funding: Indian startups experienced a 17% drop in funding in December, totaling $1.38 billion compared to $1.66 billion in November.
  2. Robust Activity in Indian Healthcare Sector: The healthcare sector in India saw significant deal activity in 2024, with $5.67 billion invested in various healthcare firms.
  3. India Stands Out in Asia-Pacific PE Deals: India accounted for 26% of the total private equity deal volume in the healthcare sector in the Asia-Pacific region.
  4. Positive Outlook for Indian Healthcare Sector: Industry experts predict a continued growth trajectory for the Indian healthcare sector in the coming year.
  5. Strong Performance in India’s IPO Market: The IPO market in India had a successful run in 2024 and is projected to maintain its momentum in 2025 with record-breaking volumes.
  6. LP-GP News: Impact-focused private capital investors are gearing up for secondaries transactions, opening up new opportunities in the impact investment space.
  7. Bain Capital Explores Investments in Indonesia: Bain Capital is looking into investment opportunities beyond healthcare in Indonesia.
  8. Chinese Semiconductor Fund Backs New Ventures: China’s state-backed investment fund for chipmaking has started backing new funds amid increasing pressures from the US.
  9. BlackRock’s Exit from Net Zero Asset Managers Initiative: BlackRock, the world’s largest asset manager, announced its departure from an environmentally-focused investor group.
  10. Funding Updates in Southeast Asia and Beyond: Various companies in Indonesia, Singapore, Vietnam, and other regions announce new rounds of funding and strategic initiatives.

APAC Private Markets Research

Explore latest Insights on APAC Private Markets on Smartkarma

Explore Now

Disclaimer:This article by is general in nature and based on publicly available information and not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material. While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Analytics and News
  • ✓ Events & Webinars
Sign Up for Free

Also, check out the latest in ECM Research on Smartkarma